Literature DB >> 23750312

Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.

Shinichi Sato1, Tsubasa Inokuma, Nobumasa Otsubo, Dennis R Burton, Carlos F Barbas.   

Abstract

Herein we describe the design and application of two small-molecule anti-HIV compounds for the creation of chemically programmed antibodies. N-acyl-β-lactam derivatives of two previously described molecules BMS-378806 and BMS-488043 that inhibit the interaction between HIV-1 gp120 and T-cells were synthesized and used to program the binding activity of aldolase antibody 38C2. Discovery of a successful linkage site to BMS-488043 allowed for the synthesis of chemically programmed antibodies with affinity for HIV-1 gp120 and potent HIV-1 neutralization activity. Derivation of a successful conjugation strategy for this family of HIV-1 entry inhibitors enables its application in chemically programmed antibodies and vaccines and may facilitate the development of novel bispecific antibodies and topical microbicides.

Entities:  

Keywords:  anti-HIV agent; bioconjugation; chemically programmed antibody; entry inhibitor; microbicide

Year:  2013        PMID: 23750312      PMCID: PMC3673733          DOI: 10.1021/ml400097z

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  35 in total

1.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

Review 3.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 4.  HIV chemotherapy.

Authors:  D D Richman
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

5.  Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.

Authors:  Subhash C Sinha; Sanjib Das; Lian-Sheng Li; Richard A Lerner; Carlos F Barbas
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

6.  Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120.

Authors:  Jingsong Wang; Nhut Le; Alonso Heredia; Haijing Song; Robert Redfield; Lai-Xi Wang
Journal:  Org Biomol Chem       Date:  2005-04-12       Impact factor: 3.876

7.  Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.

Authors:  Tao Wang; Zhongxing Zhang; Owen B Wallace; Milind Deshpande; Haiquan Fang; Zheng Yang; Lisa M Zadjura; Donald L Tweedie; Stella Huang; Fang Zhao; Sunanda Ranadive; Brett S Robinson; Yi-Fei Gong; Keith Ricarrdi; Timothy P Spicer; Carol Deminie; Ronald Rose; Hwei-Gene Heidi Wang; Wade S Blair; Pei-Yong Shi; Pin-Fang Lin; Richard J Colonno; Nicholas A Meanwell
Journal:  J Med Chem       Date:  2003-09-25       Impact factor: 7.446

8.  Tyrosine bioconjugation through aqueous ene-type reactions: a click-like reaction for tyrosine.

Authors:  Hitoshi Ban; Julia Gavrilyuk; Carlos F Barbas
Journal:  J Am Chem Soc       Date:  2010-02-10       Impact factor: 15.419

9.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).

Authors:  Alicia Regueiro-Ren; Qiufen M Xue; Jacob J Swidorski; Yi-Fei Gong; Marina Mathew; Dawn D Parker; Zheng Yang; Betsy Eggers; Celia D'Arienzo; Yongnian Sun; Jacek Malinowski; Qi Gao; Dedong Wu; David R Langley; Richard J Colonno; Caly Chien; Dennis M Grasela; Ming Zheng; Pin-Fang Lin; Nicholas A Meanwell; John F Kadow
Journal:  J Med Chem       Date:  2013-02-07       Impact factor: 7.446

10.  An effective procedure for the acylation of azaindoles at C-3.

Authors:  Zhongxing Zhang; Zhong Yang; Henry Wong; Juliang Zhu; Nicholas A Meanwell; John F Kadow; Tao Wang
Journal:  J Org Chem       Date:  2002-08-23       Impact factor: 4.354

View more
  8 in total

1.  Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Authors:  Shigehiro Asano; Julia Gavrilyuk; Dennis R Burton; Carlos F Barbas
Journal:  ACS Med Chem Lett       Date:  2014-02-13       Impact factor: 4.345

Review 2.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

3.  Illuminating HIV gp120-Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules.

Authors:  Christopher G Parker; Markus K Dahlgren; Ran N Tao; Don T Li; Eugene F Douglass; Takuji Shoda; Navneet Jawanda; Krasimir A Spasov; Sangil Lee; Nannan Zhou; Robert A Domaoal; Richard E Sutton; Karen S Anderson; William L Jorgensen; Mark Krystal; David A Spiegel
Journal:  Chem Sci       Date:  2014-06-01       Impact factor: 9.825

4.  N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.

Authors:  Tsubasa Inokuma; Roberta P Fuller; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2015-03-10       Impact factor: 2.823

Review 5.  The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell; Mark Krystal
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.

Authors:  David R Langley; S Roy Kimura; Prasanna Sivaprakasam; Nannan Zhou; Ira Dicker; Brian McAuliffe; Tao Wang; John F Kadow; Nicholas A Meanwell; Mark Krystal
Journal:  Proteins       Date:  2014-12-23

Review 7.  Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives.

Authors:  J B Senthil Kumar; Parthasarathi Das; Vibha Tandon
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

Review 8.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.